Longevity Vision Fund, one of the few life extension-focused funds in the world, invests in Juvenescence, a biopharmaceutical company that builds a pipeline of therapeutic assets to target aging, regeneration and the diseases of aging to increase human longevity.
After closing the $100m Series B investment round, the UK-based company is being valued at $500m and due to be listed on the stock market next year. Having raised $165m from its inception, Juvenescence plans to use the latest funding round to advance a number of anti-aging programs.
Founded by British billionaire Jim Mellon in 2017, the company is creating a so-called “longevity ecosystem” — a network of interlinked companies (created, acquired or in partnership with Juvenescence) with longevity-related therapeutics that are coordinated by a group of scientists, drug developers, AI specialists and financial experts.
Additional information can be found here.
Sergey Young spoke with Nicola Bagala from Lifespan.io about Longevity Vision Fund and includes a sneak peak of his upcoming book, "Growing Young"
Longevity Vision Fund, one of the few life extension-focused funds in the world, announced it had invested into Insilico Medicine, a pioneer in next-generation artificial intelligence technology fo...
Everything from the food we eat to the air we breathe is getting better. Everything from the food we eat to the air we breathe is getting better. Sergey Young, recently shared his thoughts on a Longevity Revolution, why the future of longevity looks so exciting, and why our environment will help us live longer and healthier than ever!